Who are TBI-1301's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MB-102 DMID, KI1106 4g, QD, HP-802-247, SCTB14, mini CYVE, without 3 maintenance courses, MB-102 OMID.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tbi-1301.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

TBI-1301 — Competitive Intelligence Brief

TBI-1301 (TBI-1301) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47 antibody. Area: Oncology.

phase 3 CD47 antibody CD47 Oncology Biologic Live · refreshed every 30 min

Target snapshot

TBI-1301 (TBI-1301) — Takara Bio Inc.. TBI-1301 is a monoclonal antibody targeting CD47.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TBI-1301 TARGET	TBI-1301	Takara Bio Inc.	phase 3	CD47 antibody	CD47
MB-102 DMID	MB-102 DMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	monoclonal antibody	CD47
KI1106 4g, QD	KI1106 4g, QD	Kuhnil Pharmaceutical Co., Ltd.	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis
HP-802-247	HP-802-247	Healthpoint	phase 3	CD47 antibody	CD47
SCTB14	SCTB14	Sinocelltech Ltd.	phase 3	CD47/SIRPα axis inhibitor	CD47/SIRPα axis
mini CYVE, without 3 maintenance courses	mini CYVE, without 3 maintenance courses	Gustave Roussy, Cancer Campus, Grand Paris	phase 3	CD47/SIRPα inhibitor	CD47
MB-102 OMID	MB-102 OMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	CD47 inhibitor	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47 antibody class)

Akeso · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Healthpoint · 1 drug in this class
Shenzhen Hornetcorn Bio-technology Company, LTD · 1 drug in this class
Takara Bio Inc. · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TBI-1301 — Competitive Intelligence Brief. https://druglandscape.com/ci/tbi-1301. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab